Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts

被引：2

作者：

Ghalamfarsa, Farideh ^{[1
]}

Khatami, Seyyed Hossein ^{[2
]}

Vakili, Omid ^{[3
]}

Taheri-Anganeh, Mortaza ^{[1
]}

Tajbakhsh, Amir ^{[4
]}

Savardashtaki, Amir ^{[1
]}

Fazli, Yousef ^{[5
]}

Uonaki, Leila Rezaei ^{[6
]}

Shabaninejad, Zahra ^{[4
,7
]}

Movahedpour, Ahmad ^{[1
,8
]}

Ghalamfarsa, Ghasem ^{[9
]}

机构：

[1] Shiraz Univ Med Sci, Sch Adv Med Sci & Technol, Dept Med Biotechnol, Shiraz, Iran

[2] Shahid Beheshti Univ Med Sci, Sch Med, Dept Clin Biochem, Tehran, Iran

[3] Isfahan Univ Med Sci, Sch Pharm Pharmaceut Sci, Dept Clin Biochem, Esfahan, Iran

[4] Shiraz Univ Med Sci, Pharmaceut Sci Res Ctr, Shiraz, Iran

[5] Dena Clin Diagnost Lab, Yasuj, Iran

[6] Shahrekord Univ, Sch Sci, Dept Biotechnol, Shahrekord, Iran

[7] Tarbiat Modares Univ, Fac Biol Sci, Dept Nanobiotechnol, Tehran, Iran

[8] Shiraz Univ Med Sci, Student Res Comm, Shiraz, Iran

[9] Yasuj Univ Med Sci, Sch Med, Dept Microbiol & Immunol, Yasuj, Iran

来源：

IMMUNOTHERAPY | 2021年 / 13卷 / 16期

关键词：

bispecific antibodies; carcinoembryonic antigen; colorectal cancer; humanized antibody; immunotherapy; monoclonal antibody; solid tumor; PHASE-I TRIAL; CARCINOEMBRYONIC ANTIGEN; GROWTH-FACTOR; T-CELLS; MONOCLONAL-ANTIBODIES; CLINICAL DEVELOPMENT; POTENT ANTITUMOR; LOCK METHOD; EGFR; CONSTRUCTS;

D O I：

10.2217/imt-2021-0107

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Colorectal cancer (CRC) is identified as a life-threatening malignancy. Despite several efforts and proceedings available for CRC therapy, it is still a health concern. Among a vast array of novel therapeutic procedures, employing bispecific antibodies (BsAbs) is currently considered to be a promising approach for cancer therapy. BsAbs, as a large family of molecules designed to realize two distinct epitopes or antigens, can be beneficial microgadgets to target the tumor-associated antigen pairs. On the other hand, applying the immune system's capabilities to attack malignant cells has been proven as a tremendous development in cancer therapeutic projects. The current study has attempted to overview some of the approved BsAbs in CRC therapy and those under clinical trials. For this purpose, reputable scientific search engines and databases, such as PubMed, ScienceDirect, Google Scholar, Scopus, etc., were explored using the keywords 'bispecific antibodies', 'colorectal cancer', 'immunotherapy' and 'tumor markers'.

引用

页码：1355 / 1367

页数：14

共 101 条

[1] Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer [J].

Azzariti, Amalia ;

Porcelli, Letizia ;

Brunetti, Oronzo ;

Del Re, Marzia ;

Longo, Vito ;

Nardulli, Patrizia ;

Signorile, Michele ;

Xu, Jian-Ming ;

Calabrese, Angela ;

Quatrale, Anna Elisa ;

Maiello, Evaristo ;

Lorusso, Vito ;

Silvestris, Nicola .

WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (27) :6287-6295

[2] CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors [J].

Bacac, Marina ;

Klein, Christian ;

Umana, Pablo .

ONCOIMMUNOLOGY, 2016, 5 (08)

[3] A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors [J].

Bacac, Marina ;

Fauti, Tanja ;

Sam, Johannes ;

Colombetti, Sara ;

Weinzierl, Tina ;

Ouaret, Djamila ;

Bodmer, Walter ;

Lehmann, Steffi ;

Hofer, Thomas ;

Hosse, Ralf J. ;

Moessner, Ekkehard ;

Ast, Oliver ;

Bruenker, Peter ;

Grau-Richards, Sandra ;

Schaller, Teilo ;

Seidl, Annette ;

Gerdes, Christian ;

Perro, Mario ;

Nicolini, Valeria ;

Steinhoff, Nathalie ;

Dudal, Sherri ;

Neumann, Sebastian ;

von Hirschheydt, Thomas ;

Jaeger, Christiane ;

Saro, Jose ;

Karanikas, Vaios ;

Klein, Christian ;

Umana, Pablo .

CLINICAL CANCER RESEARCH, 2016, 22 (13) :3286-3297

[4]

Bakhshinyan D, 2018, METHODS MOL BIOL, V1692, P1, DOI 10.1007/978-1-4939-7401-6_1

[5] Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC). [J].

Bendel, Johanna C. ;

Sauri, Tamara ;

Cubillo, Antonio ;

Lopez-Lopez, Carlos ;

Alfonso, Pilar Garcia ;

Hussein, Maen A. ;

Limon, M. Luisa ;

Cervantes, Andres ;

Montagut, Clara ;

Santos, Cristina ;

Bessudo, Alberto ;

Modiano, Manuel R. ;

Moons, Veerle ;

Andel, Johannes ;

Jaafar .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[6] Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report [J].

Bezan, Angelika ;

Hohla, Florian ;

Meissnitzer, Thomas ;

Greil, Richard .

BMC CANCER, 2013, 13

[7]

Brand TM, 2011, DISCOV MED, V12, P419

[8] Integrated bio-affinity nano-platform into a microfluidic immunosensor based on monoclonal bispecific trifunctional antibodies for the electrochemical determination of epithelial cancer biomarker [J].

Bravo, Karina ;

Ortega, Francisco G. ;

Messina, German A. ;

Sanz, Maria I. ;

Fernandez-Baldo, Martin A. ;

Raba, Julio .

CLINICA CHIMICA ACTA, 2017, 464 :64-71

[9] MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors [J].

Brischwein, K ;

Schlereth, B ;

Guller, B ;

Steiger, C ;

Wolf, A ;

Lutterbuese, R ;

Offner, S ;

Locher, M ;

Urbig, T ;

Raum, T ;

Kleindienst, P ;

Wimberger, P ;

Kimmig, R ;

Fichtner, I ;

Kufer, P ;

Hofmeister, R ;

da Silva, AJ ;

Baeuerle, PA .

MOLECULAR IMMUNOLOGY, 2006, 43 (08) :1129-1143

[10] Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class [J].

Brischwein, Klaus ;

Parr, Larissa ;

Pflanz, Stefan ;

Volkland, Jorg ;

Lumsden, John ;

Klinger, Matthias ;

Locher, Mathias ;

Hammond, Scott A. ;

Kiener, Peter ;

Kufer, Peter ;

Schlereth, Bernd ;

Baeuerle, Patrick A. .

JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) :798-807

← 1 2 3 4 5 6 7 8 9 10 →